Your shopping cart is currently empty

Formoterol fumarate (Eformoterol Hemifumarate), an effective, specific and long-acting β2-adrenoceptor agonist, is utilized in the treatment of chronic obstructive pulmonary disease(COPD) and asthma.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $34 | In Stock | In Stock | |
| 10 mg | $56 | In Stock | In Stock | |
| 25 mg | $123 | In Stock | In Stock | |
| 50 mg | $228 | In Stock | In Stock | |
| 100 mg | $342 | In Stock | In Stock | |
| 200 mg | $497 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $37 | In Stock | In Stock |
| Description | Formoterol fumarate (Eformoterol Hemifumarate), an effective, specific and long-acting β2-adrenoceptor agonist, is utilized in the treatment of chronic obstructive pulmonary disease(COPD) and asthma. |
| In vitro | In guinea pig lungs, Formoterol at a concentration of 100 mg/mL inhibits Platelet-Activating Factor (PAF)-induced eosinophil aggregation and suppresses Porcine Pancreatic Elastase (PPE) activity for 2-4 hours. In conscious guinea pigs, Formoterol dose-dependently inhibits histamine-induced plasma protein leakage and bronchoconstriction. Significant inhibition of histamine-induced effects was observed at doses of 10 mg/mL and 100 mg/mL. Additionally, a higher concentration of Formoterol is required to inhibit neutrophil aggregation (induced by Lipopolysaccharides) compared to its ability to suppress granulocyte-independent PPE (induced by histamine). |
| In vivo | Formoterol is a high-affinity, selective β2-adrenergic receptor agonist that effectively relaxes airway smooth muscles. Similar to salbutamol and salmeterol, it relaxes guinea pig trachea and human bronchi in vitro in a concentration-dependent manner and inhibits the release of antigen-induced inflammatory mediators in human lung slices. |
| Synonyms | NSC 299587, Formoterol Hemifumarate, CGP 25827A |
| Molecular Weight | 804.88 |
| Formula | 2C19H24N2O4·C4H4O4 |
| Cas No. | 43229-80-7 |
| Smiles | OC(=O)\C=C\C(O)=O.COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1.COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 1 mg/mL (insoluble or slightly soluble) Ethanol: < 1 mg/mL (insoluble or slightly soluble) DMSO: 247.50 mg/mL (307.50 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.00 mg/mL (2.48 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.